Ben Nicholson

Ben Nicholson has a diverse and extensive work experience in the pharmaceutical industry. Ben is currently serving as the Vice President of Drug Discovery at Xilio Therapeutics since January 2023. Prior to this, they held the position of Vice President of Pharmacology at Xilio Therapeutics from September 2020 to January 2023.

Before joining Xilio Therapeutics, Ben worked at Merck as a Principal Scientist from August 2014 to September 2020.

Earlier in their career, Ben held various roles at Progenra, Inc., starting as an Assistant Director from October 2005 to December 2006 and later serving as an Associate Director from December 2006 to October 2007. Ben then became the Director of Biology from October 2007 to April 2011 and subsequently the Senior Director of R&D from April 2011 to July 2014.

Ben's first professional experience was at Nereus Pharmaceuticals, where they began as a Research Scientist II from July 2002 to December 2004. Ben then advanced to the position of Research Scientist III from January 2005 to August 2005.

Overall, Ben Nicholson has a strong background in drug discovery, pharmacology, and R&D, with progressively significant roles throughout their career.

Ben Nicholson completed their education at the University of Bristol. Ben achieved a Bachelor of Science (BSc) degree in Biochemistry from 1990 to 1993. Subsequently, they pursued a higher level of education at the same institution and obtained a Doctor of Philosophy (PhD) degree in Biochemistry from 1993 to 1997. There is no available information regarding any education prior to their time at the University of Bristol or any further education after obtaining their PhD. Additionally, there is mention of Ben Nicholson having some connection to UC San Diego, but no specific details about their education or degree program are provided.